ZTS
NYSE · Pharmaceuticals
Zoetis Inc
$82.83
-6.37 (-7.14%)
Performance
1D
-7.14%
1W
+5.11%
1M
+16.12%
3M
+14.00%
6M
+8.03%
1Y
-31.26%
YTD
-34.22%
Open$86.62
Previous Close$89.20
Day High$88.74
Day Low$82.31
52W High$146.11
52W Low$68.77
Volume—
Avg Volume3.44M
Market Cap32.24B
P/E Ratio12.32
EPS$6.08
SectorPharmaceuticals
Technical Indicators
Full analysis →
SMA 50
$75.51
Above
SMA 200
$92.94
Below
RSI (14)
76.4
Overbought
Trend
Death Cross
Bearish
Analyst Ratings
Hold
23 analysts
Price Target
+153.4% upside
Current
$82.83
$82.83
Target
$209.87
$209.87
$137.04
$209.87 avg
$267.95
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 8.63B | 8.18B | 12.02B |
| Net Income | 2.44B | 2.08B | 3.02B |
| Profit Margin | 28.2% | 26.8% | 25.1% |
| EBITDA | 3.18B | 2.86B | 4.97B |
| Free Cash Flow | — | — | 2.28B |
| Rev Growth | +5.4% | +5.4% | +1.9% |
| Debt/Equity | 2.72 | 2.72 | 0.56 |
Dividend
Dividend Yield1.64%
Annual Dividend$2.04
Payout Ratio33.3%
Frequencyquarterly
Ex-Dividend—
Pay Date—
About Zoetis Inc
Zoetis Inc. is the world's largest animal health company, headquartered in Parsippany, New Jersey, focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostics for livestock and companion animals. The company serves veterinarians, farmers, and pet owners across more than 100 countries through a diverse portfolio of over 300 product lines. Zoetis operates across two major segments: livestock and companion animal products, with companion animals representing a growing share of revenue. Its scale, global reach, and research and development capabilities position it as the dominant player in the animal health industry.
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,388.58 | -2.07% | 50.2 | 1.34T |
| JNJ | Johnson & Johnson | $275.13 | -0.43% | 41.3 | 665.03B |
| MRK | Merck & Co. Inc. | $149.40 | -0.64% | 117.2 | 371.99B |
| PFE | Pfizer Inc. | $30.41 | -1.23% | 40.0 | 173.27B |
| BMY | Bristol-Myers Squibb Co | $63.61 | -0.90% | 13.8 | 128.00B |
| RPRX | Royalty Pharma Plc- Cl A | $67.56 | +1.75% | 47.6 | 38.75B |
ZTS Frequently Asked Questions
What does Zoetis do?
Zoetis develops and sells medicines, vaccines, and diagnostics for animals — both livestock used in food production and the companion animals that owners treat with increasing medical sophistication. The companion animal segment has become the company's fastest-growing area, driven by humanization of pets and rising veterinary spending on treatments like the blockbuster Apoquel and Cytopoint franchises for dermatological conditions. Livestock products address productive diseases across cattle, poultry, and swine, sold into global protein production systems where disease control is economically critical.
Is ZTS stock a good investment?
Zoetis benefits from the secular growth of pet ownership and the premiumization of veterinary care, with pet owners increasingly willing to spend on treatments that extend or improve their animals' lives. The company has demonstrated strong pricing power and consistent revenue growth. However, the stock typically carries a premium valuation that reflects these qualities, leaving limited margin for error if growth slows. Competition from Elanco, Merck Animal Health, and Boehringer Ingelheim has intensified in companion animal drugs, which could pressure margins in key product categories.
Who are Zoetis' main competitors?
Boehringer Ingelheim Animal Health is Zoetis' most capable global competitor, with a broad portfolio across livestock and companion animals. Merck Animal Health competes across vaccines and pharmaceuticals for both market segments. Elanco Animal Health, formed from Eli Lilly's animal health division, competes particularly in livestock. IDEXX Laboratories dominates the companion animal diagnostics space. Virbac competes in European and emerging markets.
Does Zoetis pay dividends?
Zoetis has paid a quarterly dividend since its 2013 spinoff from Pfizer, with consistent annual increases as earnings and free cash flow have grown. The yield is modest at current valuations, reflecting the market's willingness to pay a growth premium for the company's animal health market leadership. Management has balanced dividend growth with share repurchases and investment in the innovation pipeline, including biologics and diagnostics capabilities. The dividend is considered well-covered given the company's free cash flow generation.
What is the current share price of ZTS?
ZTS is currently trading at $82.83, down 7.14% in today's session. Over the past 52 weeks, the stock has traded between a low of $68.77 and a high of $146.11. The current price represents 18% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
Is ZTS rated a buy or sell by analysts?
Among 23 analysts covering ZTS, the consensus rating is Hold — 11 rate it a buy, 12 hold, and 0 sell. The average price target sits at $209.87, implying 153% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
What are Zoetis Inc's earnings?
Zoetis Inc generated $8.63B in revenue during fiscal year 2026, with $2.44B reaching the bottom line as net income. The net profit margin of 28.2% is strong by most industry standards.
How is ZTS valued compared to earnings?
ZTS trades at a P/E ratio of 12.32 on trailing earnings of $6.08 per share. That's below the S&P 500 average, suggesting the market may see limited growth or is pricing in sector-specific risks. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.
What is ZTS's return over the past year?
ZTS has struggled over the past year, though recent gains suggest a potential recovery. Returns by timeframe: -7.14% (1D), +5.11% (1W), +16.12% (1M), +14.00% (3M), +8.03% (6M), -31.26% (1Y), -34.22% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether ZTS is outperforming or lagging the broader market.